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Summary 
Structural variants of an agonist peptide-major histocompatibility complex (MHC)  molecule 
ligand can show partial agonist and/or antagonist properties. A number of such altered ligands 
appear to  act as pure  antagonists.  They lack any detectable  ability to  induce  T  cell effector 
function and have been described as unable to induce calcium transients and turnover of inosi- 
tol phosphates. This has been interpreted as an inability of these ligands to initiate any T  cell re- 
ceptor (TCR)-dependent signal transduction, with their antagonist properties ascribed to com- 
petition with offered agonist for TCR  occupancy. Yet antagonists for mature CD8 + T  cells 
can induce positive selection of thymocytes, implying active induction ofT cell differentiation 
events,  and partial  agonists  or agonist/antagonist  combinations  elicit  a  distinctive  pattern  of 
early TCR-associated tyrosine phosphorylation events in CD4 + T  cells. We have therefore di- 
rectly examined proximal TCR signaling in a CD8 + T  cell line in response to various related 
ligands. TCR engagement with natural peptide-MHC class I agonist resulted in the same pat- 
tern of early TCR-associated tyrosine phosphorylation events as seen with CD4 + cells, includ- 
ing  accumulation  of both  the  p21  and  p23  forms  of phosphorylated ~,  phosphorylation  of 
CD3e, and association ofphosphorylated ZAP-70 with the TCR. Two antagonists that lacked 
the ability to induce any detectable CTL effector response (cytolysis, esterase release, ~/inter- 
feron secretion, interleukin-2 receptor o~ upregulation) were nevertheless found to also induce 
TCR-dependent phosphorylation events. In these cases, there was preferential accumulation of 
the p21 form of phospho-~ without net phosphorylation of CD3e, as well as the association of 
nonphosphorylated ZAP-70 kinase with the receptor. These data show that variant ligands in- 
duce  similar TCR-dependent  phosphorylation  events  in  CD8 +  T  cells  as  first  observed in 
CD4 + cells. More importantly, they demonstrate that some putatively pure antagonists are ac- 
tually a subset of partial agonists able to induce intracellnlar biochemical changes through the 
TCR.  This delivery of a partial signal by antagonists raises  the possibility that antagonism in 
some cases may result from active interference with stimulation ofeffector activity by agonist in 
mature T  cells,  while the same variant signal could selectively trigger intracellular events that 
allow positive without negative selection in thymocytes. 
O 
ver the last few years the traditional TCR occupancy 
model for T  cell  activation has been  challenged  by 
the observation that subtle changes in the MHC or peptide 
component  of a  TCR  ligand  can  give  rise  to  antagonist 
ligands that no longer elicit any measurable T  cell effector 
function  but  can  diminish  the  response  to  the  original 
ligand  (1-5). Consistent with their inability to elicit T  cell 
effector functions, several peptide antagonists fail to induce 
TCR-dependent  signaling  events  such  as  the  generation 
of Ca  2+  fluxes and turnover of inositol phosphates  (1,  3). 
These observations have led some investigators to conclude 
that  antagonism  is  due  to  nonproductive  engagement  of 
the TCR by antagonist ligands, which competes with pro- 
ductive engagement by real agonists and spoils the forma- 
tion  of signaling  oligomers  (1,  6,  7).  However,  peptides 
that act as pure antagonists for mature T  cells can positively 
select  immature  thymocytes  bearing  the  same  TCR, 
whereas agonist ligands act as negatively selecting elements 
in the same system (8-10). These results are difficuk to rec- 
oncile with the presumed failure  of antagonists  to deliver 
signals  through  the  TCR,  unless  it is  assumed  that  these 
ligands positively select thymocytes by antagonizing a dele- 
tional signal induced by other thymic ligand(s) (11). 
Partial agonists, which selectively induce certain effector 
functions  or  anergy  in  T  cells  (2,  12-15),  have  recently 
been shown to deliver signals  through the TCR  that give 
rise to a distinct pattern ofphosphorylation of TCR-associ- 
ated  and  recruited  proteins  (16,  17).  These  observations 
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extended to either CD8 + cells, for which almost no data on 
peptide-MHC  ligand-induced tyrosine phosphorylation is 
available, or to  antagonist ligands that  induce  no  measur- 
able mature T  cell effector function.  In the present study, 
we have examined whether TC1K signaling can be detected 
in CD8 + T  cells in response to antagonists and report that 
ligands able to inhibit but not induce effector responses of a 
CD8 +  T  cell line elicit a  distinctive subset of biochemical 
signals through  the  TCR.  These  signals are  characterized 
by a selective increase in the p21 form ofphosphorylated 4, 
little or  no  steady-state phosphorylation  of CD3e  chains, 
and recruitment of ZAP-70 to the TCR  complex without 
subsequent stable phosphorylation, results strikingly similar 
to those obtained with CD4 + T  cell clones in response to 
partial agonists or mixtures ofagonist and antagonist (16, 17). 
These  findings demonstrate  that  the failure to  observe ef- 
lector functions  or downstream  events such  as Ca  2+  tran- 
sients  or  inositol  triphosphate  hydrolysis  in  response  to 
peptide antagonists does not necessarily indicate an absolute 
lack of TC1K signaling induced by these ligands.  Our ob- 
servations  raise  the  possibilities  that  first,  partial  signals 
transduced in response to antagonists may in some cases ac- 
tively interfere with  signaling by agonist ligands, and  sec- 
ond, the advantage of antagonists over agonists in inducing 
net positive selection may be due to the delivery of qualita- 
tively different signals to developing thymocytes that pro- 
mote differentiation without death. 
Materials and Methods 
Medium.  R.PMI  1640  medium  (Biofluids, Rockville, MD) 
was  supplemented with 2  mM  glutamine,  10  mM  nonessential 
amino acids, 10 mM HEPES, 10 mM sodium pymvate, 100 U/ml 
penicillin, 100  Ixg/ml streptomycin, 10% FCS  (all from Bioflu- 
ids), and 10 ~M 2-ME. 
Peptides.  The  OVA peptide 257-264  (SIINFEKL) (18)  was 
synthesized by Dr. J.  Coligan, National Institute of Allergy and 
Infectious Diseases (NIAID), National Institutes of Health (NIH), 
Bethesda,  MD.  Variant  peptides  P6  (SIINFPKL),  D7  (SIIN- 
FEDL), and V-OVA (R.GYNYEKL, containing the three domi- 
nant TCR. contact residues from SIINFEKL in the context of an 
unrelated, Kb-binding peptide from vesicular stomatitis virus [3]) 
were obtained from Chiron Mimotopes Peptide Systems (San Di- 
ego, CA). These peptides have previously been used to study an- 
tagonism of CTL clones specific for SIINFEKL plus K  b (3). The 
control Kb-binding peptide SENDAl (FAPGNYPAL; Sendai vi- 
rus  nucleoprotein 324-332  [19])  was a gift from Dr.  David H. 
Margulies, NIAID, NIH, and has an affinity for K  b similar to that 
of SIINFEKL (20). 
Cell Lines.  MCW, a CTL line specific for SIINFEKL plus K  b, 
was generated from B6 mice immunized with vaccinia expressing 
the SIINFEKL epitope and has  been in culture for over a year 
(21).  It expresses  high levels of CD3e, TCR., CD8cx, and CD8]3 
and is uniformly V/36 + despite the fact that it has not been cloned 
by limiting dilution (data not shown). The line was maintained in 
24-well plates (Costar Corp., Cambridge, MA) in medium con- 
taining 7.5% T-Stim  TM  (Collaborative Biomedical Products-Bec- 
ton Dickinson Labware, Bedford,  MA)  and was stimulated bi- 
weekly with irradiated (2,000  rad) C57BL/6  spleen cells pulsed 
for 30-60 rain with 10 DM SIINFEKL. The MCW line was ex- 
panded for experiments by transferring cells from each well to 25- 
cm  2 flasks (Coming Inc., Coming, NY) with peptide-pulsed irra- 
diated stimulators and culturing upright for 3 d as for stimulation 
on plates. On day 3, fresh medium with T-Stim  TM  to a final con- 
centration of 15% was added, the cells were resuspended, and the 
cultures were incubated lying down for a further 4 d. 
1KMA cells (H-2  b) (22) or 1-3, an L cell line transfected with 
K  b (23),  were used as APCs for MCW  in functional and bio- 
chemical tests. 
Cytolysis  Assays.  Targets were labeled for 1-2 h at 37~  with 
"~  txCi  of  [51Cr]sodium  chromate  (Amersham,  Arlington 
Heights, IL) in the presence (antagonism assay) or absence (ago- 
nism assay) of the concentrations of SIINFEKL peptide indicated 
in the figure legends. Following washing in PBS, 0.8-2.0  ￿  104 
targets were added to a titration of test peptides in 96-well round- 
bottom plates in a final volume of 100 txl of complete medium and 
incubated for 30-60 min at 37~  (3). MCW CTLs were subse- 
quendy added in 100 Ixl of complete medium to the final indicated 
E/T  ratio, the plates were centrifuged to promote cell contact, 
and the pelleted cells were left at 37~  for 4--6 h.  Supernatants 
were harvested, and radioactivity was counted and converted to 
percent specific release as described previously (21). In some vari- 
ations of the experiment, labeled targets were pulsed with or with- 
out SIINFEKL followed by the test peptides and washed before 
incubating with the CTLs. 
For prolonged assays in which multiple parameters of MCW 
activation were measured, cytolysis of APCs was assessed by the 
release  of lactate dehydrogenase (LDH)*  into the supernatant by 
use  of an enzymatic assay (CytoTox 96 kit; Promega, Madison, 
WI)  per the  manufacturer's instructions.  Data  are  expressed as 
percentage of the maximal release observed following subtraction 
of the release induced by targets pulsed with no peptide. 
IFN-'y Production.  MCW  cells  were  incubated  in  24-well 
plates overnight with peptide-pulsed APCs in 1 ml of complete 
medium. Supernatants were assayed for the presence of IFN-',/by 
ELISA in triplicate, using the XMGI.2 mAb (PharMingen, San 
Diego, CA) as a capture reagent. Bound  cytokine was  detected 
with a  rabbit polyclonal serum against mouse  IFN-y (kind gift 
from Dr. W.E. Paul, NIAID, NIH), followed by goat anti-rabbit 
conjugated  to  alkaline  phosphatase  (Jackson  ImmunoResearch 
Laboratories, Inc., West Grove, PA). The plates were developed 
with p-nitrophenyl phosphate  (Sigma Chemical Co.,  St.  Louis, 
MO), and the absorbance at 405 nm was recorded after 0.5-2.0 h. 
Data are  expressed as percentage  of the  maximal secretion ob- 
served after subtraction of the secretion induced by cells pulsed 
with no peptide. 
Serine Esterase Release.  MCW  cells  were  either  cultured  in 
24-well plates overnight with  APCs  as for the  IFN-~/ assay or 
were cultured in 96-well plates for 6 h with (unlabeled) targets as 
for the chromium release assays. Serine esterase release by MCW 
was measured in triplicate as previously described (3). The mean 
absorbance at 405 nm is expressed as a percentage of the maximal 
release  observed in  response  to  APCs  pulsed  with  SIINFEKL 
peptide after subtraction of the release induced by targets pulsed 
with no peptide. 
Flow Cytometry.  Propidium iodide-gated cells were analyzed 
with a FACScan  |  cytometer and Lysys  TM  software (Becton Dick- 
inson & Co., Mountainview, CA). To determine IL-2 receptor et 
(IL-2Re~;  CD25)  upregulation  following MCW  activation  by 
I  Abbreviation used in this paper: LDH, lactate dehydrogenase. 
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by washing in PBS containing 1 mM EDTA, and cells were dou- 
ble-stained with  mAbs  (from  PharMingen),  3C7  (0~CD25;  rat 
IgG2b),  followed by  PE-conjugated  goat anti-rat  (Caltag,  San 
Francisco, CA) and FITC-AF3-12.1 (ctH-2Kk; mouse IgG1). Be- 
cause  1-3 but not MCW cells express H-2  k antigens,  APCs were 
excluded from the analysis by live gating on FITC-negative cells. 
Tyrosine Phosphorylation Assays.  A modification of a previously 
described assay was employed to detect tyrosine-phosphorylated 
proteins involved in TCR  signahng (17).  In brief, 5-10  ￿  106 
MCW  cells were added to  1-3  ￿  106 peptide-pulsed APCs in 
Eppendorf tubes, cells were pelleted by centrifugation, and the 
tubes were placed in a water bath at 37~  for 5 or 10 rain. At the 
end of the incubation period, the tubes were transferred to ice, 
cells were resuspended in ice-cold PBS containing 0.4 mM EDTA 
and 0.4 mM sodium orthovanadate, and they were then re-pel- 
leted and lysed in lysis buffer (1% NP-40, 150 mM NaC1,  10 mM 
Tris-HC1, pH 7.6, 5 mM EDTA, 10 b~g/ml leupeptin, 10 p,g/ml 
aprotinin, and 1 mM orthovanadate). ZAP-70 was immunopre- 
cipitated from lysates with a rabbit polyclonal antiserum (gener- 
ous gift of Dr. U  Samelson, National Institute of Child Health and 
Human Development, NIH, or purchased from Upstate Biotech- 
nology, Lake Placid, NY). Immunoprecipitates were separated by 
SDS-PAGE  on  precast,  12  or  15%  Mini-PROTEAN*  II gels 
(Bio-Rad, Richmond, CA) under reducing conditions and West- 
ern blotted onto  nitrocellulose. The  blots were probed with a 
mouse mAb against phosphotyrosine (4G10; Upstate Biotechnol- 
ogy), followed by peroxidase-sheep anti-mouse (Amersham In- 
ternational, Buckinghamshire, England), and developed by chemi- 
luminescence (Renaissance kit; DuPont-New England Nuclear, 
Boston, MA). Quantification of  bands on fihn exposures was per- 
formed with a laser densitometer (Molecular Dynamics, Sunny- 
vale, CA). 
Results 
SIINFEKL  Variant  Peptides  V-OVA,  P6,  and  D7  Have 
No  Detectable  Agonist  Function  for  MCW  CD8  +  CTLs. 
We made use ofa CD8 +, V[36 + CTL hne generated in our 
laboratory, specific for SIINFEKL plus K b (21), to investi- 
gate the response of CD8 + T  cells to altered hgands. Jame- 
son and Bevan have mapped the primary TCtL contact sites 
of the  SIINFEKL epitope to peptide residues 4,  6,  and  7 
and reported that a large proportion of variants at these po- 
sitions can act as antagonist hgands for one  or more CTL 
clones (3,  24).  We  therefore tested three  of these variants 
we had available, V-OVA, P6,  and D7,  for their ability to 
sensitize target cells for lysis by MCW  in a standard cyto- 
toxicity assay. In various assays, using 51Cr or LDH release 
from 1-3 or ILMA targets as a measure of cytolysis and test- 
ing peptide concentrations up to 50  ~M  and assay lengths 
up  to 6  h,  we were  unable to detect any killing of targets 
pulsed with the variant peptides, despite the fact that SIIN- 
FEKL was able to sensitize targets for killing at concentra- 
tions  down  to  the  picomolar  range  (data  not  shown). 
However,  because  variant  peptide  hgands  can  selectively 
induce some T  cell effector functions and not others (2,  12, 
13,  15,  25), we examined other parameters of MCW  acti- 
vation for evidence of partial agonist function by the SIIN- 
FEKL analogues. MCW  cells were incubated overnight with 
Table 1.  SIINFEKL  Variant Peptides Fail to Act as Agonists for 
MCW CTL 
[SIINFEKL] 
Serine  IL- 
Killing  esterase  IFN-~/  2Rtx 
Mean*  SD*  Mean*  SD*  Mean*  SD*  Mean* 
0  0  0  0  0  0  0  0 
5 pM  98  1  30  0  13  1  6 
50 pM  96  2  33  0  27  3  9 
500 pM  89  3  47  0  49  2  18 
5 nM  95  2  89  1  58  3  61 
50 nM  97  1  97  1  58  2  77 
500 nM  99  2  98  0  57  3  91 
5 laM  96  1  100  1  60  1  100 
50 I.LM  100  2  100  1  100  12  80 
50 btM SENDAl  1  0  0  0  0  0  0 
50 p~M V-OVA  0  0  0  0  0  0  1 
50 b~M P6  0  0  0  0  0  0  0 
50 ~M D7  8  0  0  0  0  0  0 
106 1-3 APC were pulsed for 2 h at 37~  with the indicated peptide 
concentrations, washed in PBS, and plated with 106 MCW CTL in 1 ml 
complete medium in 24-well plates. After overnight incubation  (17 h), 
supematants were recovered and assayed for the presence of LDH (re- 
leased by the target cells) and serine esterase and IFN-~/(released by the 
CTL), as detailed in Materials and Methods. The cells were harvested, 
dissociated into a single-cell suspension in the presence of EDTA, and 
double-stained for IL-2P,  ct (CD25) and H-2K  k. IL-2tL0t expression by 
MCW was assessed  by flow cytometry after propidium iodide gating to 
exclude dead cells and live gating to exclude H-2K  k+ 1-3 targets. Data 
for all parameters are expressed as a percentage  of the maximum  re- 
sponse after subtraction of the response to unpulsed 1-3. Negative val- 
ues are expressed as zero. 
"Mean and standard deviation of triplicate determinations. 
*Mean fluorescence of 10,000 collected events. 
APCs  prepulsed with  a  titration of SIINFEKL or the  test 
peptides. The variant peptides failed to induce MCW  cells 
to release serine esterase, secrete IFN-% or upregulate the 
et  chain of the receptor for IL-2, despite the fact that  107 
times  less  SIINFEKL  peptide  (5  pM)  than  the  maximal 
tested concentration of variant peptide (50  I~M) was capa- 
ble of inducing a measurable response for each of these pa- 
rameters  (Table  1).  As before,  killing of the  variant pep- 
fide-pulsed target  cells was  also  not  induced in  this  long 
assay, despite the fact that it was the most sensitive effector 
function measurable (Table 1). D7 was also completely un- 
able  to  sensitize  1-3  or RMA  targets  to  form  conjugates 
with MCW, even though conjugates with SIINFEKL-pulsed 
targets were  easily detectable by flow cytometry (data not 
shown). Taken together, these data demonstrate that V-OVA, 
P6, and D7 are unable to elicit nuclear transcription-inde- 
pendent (cytolysis, serine esterase release, adhesion) or tran- 
scription-dependent (IFN-~/production, CD25 upregulation) 
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Figure 1.  Peptide analogues modulate cytolysis of SIINFEKL-pulsed 
target cells. (A) agonism assay (no SIINFEKL pre-pulse); and (B-D) an- 
tagonism assays (SIINFEKL pre-pulse)..4 and B are from the same ex- 
periment; C and D are from separate experiments. RMA (A, B, and D) or 
1-3 (C) targets were labeled with SlCr for 1-1.5 h in the absence (A) or 
presence (B-D)  of SIINFEKL (B and  C,  1 nM;  D,  100  nM), washed 
twice in PBS, and added in 50 ~1 of complete medium to wells of a 
microtiter plate containing 50 I*1 of a serial dilution of the indicated pep- 
tides, to give the indicated final peptide concentration. After preincuba- 
tion for 30-45  rain at 37~  MCW cells were added in 100 ILl of me- 
dium, halving the concentration of peptide. The plates were centrifuged 
and incubated at 37~  for 4~ h. Data are expressed as the mean 51Cr re- 
lease of triplicate wells converted to percent specific  release +SD. Dotted 
lines in B and C indicate the level of killing in the absence of test peptide 
during the assay. Number of targets used and E/T ratios were as follows: 
A and B, 8 ￿  10  3 targets, E/T 5:1; C, 15 ￿  10  3 targets, E/T 5:1; D, 15 ￿ 
10  3 targets, E/T 17:1. Spontaneous and maximum release values -+SD (in 
cpm): A, 2517 •  387 and 18394 •  1355; B, 2345 •  229 and 15530 -+ 
963; C, 3275 +- 363 and 29239 •  1526; D, 726  •  112 and 11755 • 
1153. 
effector functions  and  by  these  criteria would  typically be 
classified as non-agonists for MCW  cells. 
V-OVA,  P6,  and  D7  Can Act as Antagonists for MCW 
Cells.  Jameson  and  Bevan  have  demonstrated  that  some 
OVA variant peptides that  do  not  act as agonists in func- 
tional assays can nonetheless act as specific TCP,. antagonists 
(3). To test for antagonist actiwty, 51Cr-labeled targets were 
either pulsed or not with a limiting concentration of SIIN- 
FEKL and were plated with different concentrations of the 
variant peptides. CTLs were added, and cytolysis was mea- 
sured 4-6 h  later. As before, unpnlsed targets could not be 
sensitized for lysis by the variant peptides present in the as- 
say (Fig. 1 A), although, in control experiments, the inclu- 
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sion  of SIINFEKL  resulted  in  target  cell  lysis  (data  not 
shown). Three antagonism experiments using targets pulsed 
with  a  limiting  concentration  of SIINFEKL peptide  are 
shown in Fig. 1,/3-D. D7 and P6 consistently inhibited ly- 
sis in a  dose-dependent manner  (Fig. 1,  B-D).  No such ef- 
fect was seen with  the  control Kb-binding peptide,  SEN- 
DAl,  demonstrating  that  this  effect  was  due  to  TCR 
antagonism rather than  MHC  competition (Fig.  1,  B--D). 
V-OVA was  not  an  antagonist in most  experiments  (e.g., 
Fig.  1 B), although it occasionally inhibited lysis (e.g., Fig. 
1  C). Antagonism by D7 was seen in four out of four ex- 
periments and in three out of three experiments for P6. D7 
was  always the most and V-OVA the least potent antago- 
nist of the three (Fig. 1,  B-C).  As previously reported (3), 
antagonism was not due to a direct effect of the peptide on 
the  CTL,  because it could also be  seen in  experiments in 
which targets were pulsed sequentially with SIINFEKL and 
D7  and washed before addition of MCW  killers (data not 
shown).  The  fact  that  V-OVA,  P6,  and  D7  are  able  to 
modulate the response to the agonist peptide demonstrates 
that  these  analogues  are  capable  of interacting specifically 
with MCW  TCRs,  despite being unable to act as effector 
agonists per se. 
P6 and  D7  Signaling Results  in  Accumulation of the p21 
Form of Phospho-~ without  Detectable Amounts  of Tyrosine- 
Phosphorylated CD3e, and in ZAP-70 Recruitment without Its 
Net Phosphorylation.  The earliest events after TCP, engage- 
ment,  before  the  hydrolysis of phosphatidylinositol 4,5- 
bisphosphate and  generation  of Ca  2+  fluxes,  are the  rapid 
tyrosine phosphorylation of TCP,  subunit  chains  and  re- 
cruitment  of the  tyrosine kinase  ZAP-70,  followed by its 
phosphorylation and concomitant activation (26, 27). Some 
partial agonist ligands for CD4 +  T  cells have been  shown 
to induce an altered pattern of these early phosphorylation 
events  as  detected  by  anti-phosphotyrosine immunoblot- 
ting  that  may  result  in  the  selective  induction  of down- 
stream events (16,  17). Little information is available on the 
early tyrosine phosphorylation events that  follow receptor 
engagement by agonists or variant ligands in CD8 + T  cells. 
H611sberg et al. have examined stimulation of a CTL clone 
with  an  altered peptide  ligand  and  concluded  that,  as  in 
CD4 + T  cells (15), a partial agonist was capable of activat- 
ing coreceptor-associated p56 tck in a manner similar to that 
of the wild-type agonist peptide (25).  However, those au- 
thors did not report studies with antagonist ligands or,  for 
the partial agonist examined, the phosphorylation status of 
or ZAP-70.  Therefore,  to evaluate whether  the antago- 
nist peptides were capable of delivering a biochemical signal 
through  the  TCP,,  MCW  cells were  exposed to peptide- 
pulsed 1-3 cells for 10 min at 37~  ZAP-70 and associated 
molecules were  immunoprecipitated from  lysates of these 
cells; then the proteins in the precipitates were resolved by 
SDS-PAGE and blotted for the presence ofphosphorylated 
tyrosine residues.  MCW  cells exposed to  unpulsed APCs 
showed few phosphorylated protein species coprecipitating 
with ZAP-70: only the p21  form ofphospho-~ was consti- 
tutively present  (Fig. 2,  lane 2).  In contrast, incubation of 
MCW  with APCs pulsed with  10 IxM SIINFEKL resulted 
T Cells in  the  appearance  of prominent  tyrosine-phosphorylated 
species  that  coprecipitated  with  ZAP-70:  two  isoforms  of 
phospho-~,  p23  and  p21,  appeared  as  bands  of roughly 
equal intensity, and a third isoform, p18, was also present as 
a  fainter band;  CD3e  was  also  phosphorylated,  and  a  dis- 
tinct band of phosphorylated  ZAP-70  was evident  (Fig.  2, 
lane  I).  Thus,  these  CD8 +  CTLs  show  a  pattern  of early 
TCR-associated  phosphorylation  events in response to ag- 
onist ligand similar to that observed with CD4 § T  cells (16, 
17,  28).  V-OVA  did  not  induce  phosphorylation  of any 
ZAP-70  coprecipitable proteins  above background  (Fig.  2, 
lane  5).  However,  the  two  more  potent  antagonist  pep- 
tides, P6 and D7,  clearly induced  an increase in the level of 
phosphorylation  (Fig.  2,  lanes  3  and  4).  The  signal  in- 
duced  by P6  and D7 was distinct  from that seen upon  ex- 
posure to full agonist in several ways:  the two variant pep- 
tides  induced  a  disproportionate  accumulation  of the p21~ 
form over the p18~  and p23~  forms,  even after correcting 
for background p21~ levels, and clearly allowed the associa- 
tion of ZAP-70 with the receptor complex while faihng to 
induce its subsequent  stable phosphorylation,  because anti- 
ZAP-70  coprecipitated the ~ chains  even though  no phos- 
phorylated  ZAP-70  was detectable.  ~ phosphorylation  was 
also  not  accompanied  by  visible  phosphorylation  of the 
CD3~  chains.  Identical  patterns  of phosphorylation  were 
seen  in  samples  immunoprecipitated  with  anti-CD3e  in- 
stead of anti-ZAP-70  (data not shown).  Thus,  these CD8 + 
CTLs  show  a  pattern  of signaling  in  response  to  variant 
ligands  indistinguishable  from that previously  reported  for 
Figure 2.  Variant  signaling by MCW CTL in response to stimulation 
by K  b +  variant peptides, P6 and D7.  1-3 APC  (1.5 ￿  106/lane) were 
pulsed in complete medium for 1.5 h with medium alone (No ag) or the 
indicated peptides at 100 I~M (V-OVA, P6, D7) or 10 I-~M  (SIINFEKL). 
107 MCW cells were added to  each tube  and stimulated for 5 min  at 
37~  as detailed in Materials and Methods. Proteins in lysates were im- 
munoprecipitated with an antiserum against ZAP-70, separated on a 15% 
polyacrylamide gel, and Western  blotted  onto  nitrocellulose. The blot 
was probed  with  a mAb against phosphotyrosine and  developed using 
chemiluminescence. The migration ofprestained molecular weight mark- 
ers is indicated on the right. The marks on the left identify the major ty- 
rosine-phosphorylated species. 
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CD4 + T  cell clones in response to partial agonists or certain 
agonist/antagonist  combinations  (16,  17). 
Phospho-~  induction  above  background  in  response  to 
D7  and  P6  was  observed  in  six  out  of seven  experiments 
with D7 and two of three experiments with P6, using a va- 
riety  of  APCs  and  stimulation  conditions.  In  contrast, 
phospho-~ accumulation was not detectable in any of three 
experiments  in  response  to  V-OVA  stimulation.  Interest- 
ingly,  the  degree  of ~ phosphorylation  obtained  with  the 
variant peptides correlated with their potency in the antag- 
onism  assay  (see  above).  Thus,  D7  consistently  gave  the 
highest  level  of ~  phosphorylation  and  was  also  the  most 
powerful  antagonist,  whereas  the  P6 peptide  was  of inter- 
mediate antagonist potency and elicited a weaker phosphor- 
ylation  response  (Figs.  1,  B-D,  and  2).  Antagonism  by 
V-OVA  was  inconsistent,  and  this  peptide  also  did  not 
elicit a biochemical signal from MCW  cells.  Thus,  P6 and 
D7  act as  partial  agonists  at the  level  of signahng  through 
the TCR  despite being nonagonists  at the level of multiple 
effector functions. 
The Pattern of Partial Signaling Induced by Antagonists  Ap- 
pears to Be Distinct from Low Level  Signaling Induced by Ago- 
hist.  Although  the  pattern  of  early  phosphorylation  of 
TCR  complex chains induced  by P6 and D7 appeared dis- 
tinctly different from that in response to the SIINFEKL ag- 
onist  peptide,  it  was  possible  that  it  simply  represented 
weak signaling events insufficient to induce a functional re- 
sponse.  If so,  titrating  the  SIINFEKL peptide  down  to  a 
dose  where  it  no  longer  elicited  a  measurable  response 
should  result  in  a  pattern  of phosphorylation  identical  to 
that seen in response  to P6  or D7.  To  address this  issue,  a 
phosphorylation  assay was run  in parallel with  the  effector 
assays shown in Table 1. MCW  cells were incubated for 10 
rain with the same peptide-pulsed  1-3 cells used as APCs in 
the  functional  assay,  and  ZAP-70  and  associated  proteins 
were immunoprecipitated from lysates and blotted for phos- 
photyrosine  residues  as before.  Fig.  3  shows that the set of 
phosphorylated  species  associated  with  ZAP-70  decreased 
in  parallel  with  decreasing  doses  of  offered  SIINFEKL 
(lower gel, lanes  1-8).  Once again, D7 but not V-OVA or 
the control SENDAl peptide induced  ~ chain phosphoryla- 
tion above background  (Fig.  3  top). Importantly, whereas 5 
pM of SIINFEKL gave a barely detectable biochemical sig- 
nal  (Fig.  3, lower gel, lane 2), it still induced  maximal kill- 
ing in the  cytolysis assay that was run in parallel  (Table  1). 
Thus, when using conventional agonist ligand,  the cytolysis 
assay is  more  sensitive  that  the  phosphorylation  assay as  a 
measure  of TCR  signaling.  Yet  at the  same time,  we  ob- 
serve  definite  TCR-dependent  phosphorylation  of the 
chain when using D7, in the absence of any measurable cell 
killing. Because this latter pattern of detectable ~ phosphor- 
ylation without  cytolysis is not observed across a full dose- 
response  range  for  SIINFEKL,  these  data  clearly  imply  a 
qualitative change in the relationship between TCR-induced 
biochemical changes and biological responses in the case of 
D7 presentation. 
Further  support  for  qualitative  differences  in  signaling 
between  SIINFEKL and P6  and D7  came from visual and Figure  3.  The  signaling pattern induced by 
variant peptides is not seen with low amounts 
of  full agonist. 12 ￿  10  ~ MCW cells were stim- 
ulated for 10 nfin with 3 ￿  1061-3 APC  pulsed 
for 2 h with medium alone (No ag), the test 
peptides at 50 ttM (SENDAl, V-OVA, DT), or 
varying concentrations of SIINFEKL (5 pM-51) 
IzM). Proteins in lysates were immunoprecipi- 
tated  with anti-ZAP-70,  separated on  12% 
polyacrylamide gels, and analyzed as in Fig. 2. 
In producing the figure, the "No ag" lane in 
the  top  gel was duplicated and added to  the 
lower gel to facilitate comparison. Note that the 
same peptide-pulsed 1-3  APC  were used to 
stimulate MCW for the functional part of the 
experiment, which is detailed in Table t.  The 
sample corresponding  to P6 stimulation was lost 
in this experiment. 
densitometric  analysis  of the  patterns  of phosphorylation 
induced by the two categories of ligands (Fig. 3  and Table 
2).  As before,  D7 signaling led to a preferential  accumula- 
tion  of the p21  form of phospho-~ over the p18  and  p23 
forms without phosphorylation of CD3e and with associa- 
tion of ZAP-70 with the receptor without its net phosphor- 
ylation  (Fig.  3,  upper  gel,  lane  5).  Although  decreasing 
concentrations of offered SIINFEKL also resulted  in some 
skewing  toward  the  p21  form  of phospho-~,  in  part  be- 
cause  of its  background  constitutive  phosphorylation  in 
MCW  cells,  the  accumulation  of p21  phospho-~  in  D7- 
stimulated samples was still accompanied by proportionately 
less p23~ than in samples stimulated with 0.5-5.0 nM SIIN- 
FEKL that have a similar level of p21  accumulation  (Fig. 3 
and Table  2).  Such skewing toward p21  phospho~  in re- 
sponse to partial agonist stimulation has been observed pre- 
viously in  CD4 + T  cell  clones  (16,  17).  In addition,  clear 
differences in phosphorylation of CD3e chains and ZAP-70 
could  be  seen  between  the  D7  and  the  SIlNFEKL-sfimu- 
lated samples  (Fig.  3).  Although  p21  phospho-/~  induction 
by  50  I~M  D7  matched  that  by  500  pM  SIINFEKL, the 
variant  peptide  only  induced  6  densitometric  U  of phos- 
phorylated  ZAP-70  and  0  U  of phosphorylated  CD3~, 
whereas the agonist induced 33 and 36 U, respectively (Ta- 
ble 2).  These results clearly indicate that the interactions of 
D7 and P6 with the T  cell receptors of  MCW cells result in 
an overall pattern of signaling events that differs  significandy 
from that induced by low levels ofagonist ligand. 
Discussion 
In contrast to partial  agonist ligands that induce a subset 
of T  cell functions and can,  under certain  conditions,  also 
act as TCR  antagonists, pure antagonists have been claimed 
154  Partial  Signaling by CD8 + T Cells Table 2.  Densitometric  Quantitation of Signaling Induced by 
SIINFEKL and Variant Peptides 
[SIINFEKL]  ZAP-70  CD3e  p23~  p21~  p18~ 
0  0  0  0  0  0 
5 pM  5  0  103  211  0 
50 pM  16  26  88  272  18 
500 pM  33  36  208  438  60 
5 nM  126  115  773  1113  192 
50nM  210  138  1190  1264  297 
500 nM  279  256  1413  1898  611 
5 ~M  351  234  2025  1881  678 
50 ~M  385  216  1972  1747  375 
50 IxM SENDAl  2  0  79  55  0 
50 IxM V-OVA  2  0  80  100  0 
50 I.~M D7  6  0  120  426  92 
Densitometric quantitation of the bands in Fig. 2 was performed using 
a grid to select bands across several lanes and volume integration using 
Molecular Dynamics IQ software. Data are expressed as arbitrary densi- 
tometric units alger subtraction of the response to unpulsed APC, Neg- 
ative values are expressed as zero. 
to deliver no signals  through the TCR  (1,  6, 7, 29).  Here 
we have demonstrated that several such inhibitory ligands, 
which by all tested measures lack any ability to induce ma- 
ture CTL effector function, nonetheless deliver a biochem- 
ical signal upon TCR engagement. These findings support 
the hypothesis that many antagonists are a subset of partial 
agonist peptides that elicit TCR-dependent signals  that fail 
to reach a quantitative or qualitative threshold necessary for 
stimulation of the effector functions of a mature T  cell, but 
whose  interaction  with  the  TCR  may in  some  cases  ac- 
tively interfere with the response to full agonists or induce 
differentiation events in immature lymphocytes (8-10, 30- 
32).  They also emphasize the similarity in early TCR  sig- 
naling  events between  mature  CD4 +  and  CD8 +  T  cells, 
despite earlier results suggesting that tyrosine phosphoryla- 
tion events in response to TCR  cross-linking differed be- 
tween  CD4 +  and  CD8 +  T  cells  (33),  presumably due  to 
the reportedly stronger association of p56 ~  with CD4 than 
CD8 (34). 
Although  biochemical  evidence  of signaling  was  not 
seen in response to V-OVA, which also had weak antago- 
nist  activity,  this  may reflect  the  limitations  of the  tech- 
nique used to detect signaling rather than the identification 
of an  antagonist  lacking  all  ability  to  initiate  intracellular 
biochemical changes through the TCR. We raise this pos- 
sibility because variant ligands that lacked measurable effec- 
tor-inducing activity on their own were found to be able 
to contribute to effector function in a positive way. At very 
high concentrations of the antagonist peptides studied here 
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(in particular V-OVA),  enhanced lysis of targets prepulsed 
with  a limiting  concentration  of SIINFEKL was  seen,  in 
contrast with the antagonism normally found at lower con- 
centrations  of the variant peptides  (Reis  e  Sousa,  C.,  un- 
published observations). These results suggest that although 
modified  signaling  by an  antagonist  alone  does  not  nor- 
really reach the threshold needed for induction oft  cell ef- 
fector function,  it can augment stimulation by an agonist, 
that is,  it can act as a  "cryptic" agonist.  Competition be- 
tween the antagonistic and cryptic agonistic functions of a 
variant peptide  may also  explain  why,  in  some  assays,  a 
plateau of inhibition is seemingly reached with P6, where 
increasing the concentration  of analogue beyond a certain 
threshold  does  not  result  in  further inhibition  (Fig.  1,  B 
and D). Cryptic agonist function is in some ways similar to 
the mixed antagonists/partial agonists described by Jameson 
and Bevan, which inhibit cell lysis in response to agonist at 
low  concentrations,  but  lead  to  effector activity  at  high 
concentrations  (3).  Cryptic  agonism  by  V-OVA  implies 
some ability to contribute to TCR-dependent signal gen- 
eration, even if this cannot be measured biochemicaUy un- 
der our current conditions. 
Related technical limitations of the methods available to 
evaluate protein phosphorylation in living cells are also rel- 
evant to interpretation of the specific phosphorylation pat- 
terns  seen  with  variant  and  wild-type  ligands.  Immuno- 
blotting detects the state ofTCR-associated phosphorylation 
events resulting from the simultaneous activities of tyrosine 
kinases and phosphatases over a time scale (minutes) that is 
long compared with that for the rate of enzymatic function 
of these proteins. It is thus possible that certain phosphory- 
lation events occurring following TCR engagement by an- 
tagonist ligands are both too transient and too weak to be 
detected by this method.  A  number of models have been 
proposed to  explain  how altered  signaling in  response to 
variant  ligands  can  result  from  a  low-afllnity  interaction 
with the TCR  (7,  30-32,  35).  We have recently empha- 
sized the notion that a lack of a stable state ofphosphoryla- 
tion of some substrates such as ZAP-70, rather than a fail- 
ure to phosphorylate these substrates at all, may explain the 
altered pattern of phosphorylation seen using such variant 
ligands (32).  Transient signaling may be at the heart of an- 
ergy induction by partial agonist ligands (35a),  and may also 
lead to changes in kinase  function  or substrate availability 
that  actively  inhibit  signaling  by  agonist-engaged  TCR. 
Together with our findings here that the degree of ~ phos- 
phorylation elicited by the SIINFEKL analogues correlates 
with  their  potency  as  antagonists,  these  findings  make  it 
tempting  to  speculate  that  TCR-associated  biochemical 
changes, acting in a dominant negative fashion (36),  could 
be at the root of the ability of certain variant ligands to an- 
tagonize the response to agonist. 
Finally,  the  demonstration  here  that so-called pure  an- 
tagonists for the TCR ofCD8 + T  cells, like partial agonists 
studied previously using CD4 + T  cells  (16,  17),  do induce 
TCR-dependent biochemical changes that differ from those 
seen with low levels of typical agonist, may help explain the 
potency of such altered ligands in inducing net positive se- lection of transgenic thymocytes (8-10).  The advantage of 
antagonists  or partial  agonists  defined using mature  T  cell 
activation in inducing positive selection  of immature  cells 
with the same receptor may depend on their ability to de- 
liver qualitatively different signals to developing thymocytes 
that allow maturation with a lower likelihood  of signaling 
for apoptosis.  This  proposal is  in  accord with  suggestions 
made recently based on studies of transgenic mice in which 
positive  selection  was  disrupted  using  dominant  negative 
p21 ra~ and mitogen-activated protein kinase mutations  (37, 
38).  Thus,  both activation of mature T  cells and develop- 
ment of immature T  cells may be affected by altered signal- 
ing  that  accompanies  variant  ligand  engagement  of the 
TCP,. A  more complete description of such altered signal- 
ing and  its  intracellular  effects will  clearly help  in  under- 
standing  the  molecular  events  underlying  normal  agonist 
signaling in T  cells and in determining how T  cell behavior 
is modified by variants of these more typical ligands. 
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